SML0210

BMS-299897

≥98% (HPLC)

• Synonym(e): 2-[(1R)-1-[[(4-Chlorophenyl)sulfonyl](2,5-difluorophenyl)amino]ethyl]-5-fluoro-benzenebutanoic acid
• Empirische Formel (Hill-System): C₂₄H₂₁ClF₃NO₄S
• CAS-Nummer: 290315-45-6
• Molekulargewicht: 511.94
• UNSPSC-Code: 12352200
• NACRES: NA.77

Eigenschaften

• Assay: ≥98% (HPLC)
• Form: powder
• Farbe: white to beige
• Löslichkeit: DMSO: ≥20 mg/mL
• Lagertemp.: −20°C
• SMILES String: Fc1c(cc(cc1)F)N([S](=O)(=O)c3ccc(cc3)Cl)[C@H](C)c2c(cc(cc2)F)CCCC(=O)O
• InChI: 1S/C24H21ClF3NO4S/c1-15(21-11-7-18(26)13-16(21)3-2-4-24(30)31)29(23-14-19(27)8-12-22(23)28)34(32,33)20-9-5-17(25)6-10-20/h5-15H,2-4H2,1H3,(H,30,31)/t15-/m1/s1
• InChIKey: IZAOBRWCUGOKNH-OAHLLOKOSA-N

Beschreibung

Anwendung

BMS-299897 has been used as an γ-secretase inhibitor to stop high glucose (HG) mediated amyloid β-peptide (Aβ) secretion.[1]

Biochem./physiol. Wirkung

BMS-299897 is a gamma-secretase inhibitor

BMS-299897 is a potent inhibitor of γ-secretase. The comound is 15-fold more selective for inhibiting the cleavage of β-amyloid precursor protein over Notch cleavage (IC₅₀s 7.1 and 105.9, respectively). In vivo, BMS-299897 blocks the formation of Aβ40 and Aβ42 in the brain and CSF without affecting maturation of CD8⁺ T cells or intestinal goblet cells, suggesting Notch signalling was not significantly inhibited.

BMS-299897 may be used as a therapeutic for Alzheimer′s disease.[2]

Sicherheitshinweise

• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable